U.S. Markets closed

EMA gives positive recommendation for Actavis' generic memantine

The Committee for Medicinal Products for Human Use adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Nemdatine, 5 mg, 10 mg, 15 mg and 20 mg, film-coated tablets intended for the treatment of patients with moderate to severe Alzheimer’s disease. The applicant for this medicinal product is Actavis Group. Nemdatine is a generic of Ebixa.